Pfizer's Chantix proves popular but raises concerns

02/25/2008 | Star-Ledger (Newark, N.J.), The

Pfizer's smoking-cessation drug Chantix, propelled by a multimillion-dollar ad campaign, has helped an estimated 1 million people quit smoking and brought in $883 million in sales last year. But the FDA is concerned about reports of users experiencing depression, severe mood swings and suicidal ideation and behavior. Pfizer says there is no proven association between its nicotine-free treatment and suicide.

View Full Article in:

Star-Ledger (Newark, N.J.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC